Trevi Therapeutics, Inc. Capital Expenditures
Trevi Therapeutics, Inc. (TRVI) reported Capital Expenditures of $226.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-08-06
- Trevi Therapeutics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2026-06-30 was $124.00K.
- Trevi Therapeutics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2026-03-31 was $102.00K.
- Trevi Therapeutics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- Trevi Therapeutics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-09-30 was $12.00K.
- Trevi Therapeutics, Inc. payments to acquire property, plant, and equipment for fiscal 2025 was $12.00K, a 65.71% decline from fiscal 2024.
- Trevi Therapeutics, Inc. payments to acquire property, plant, and equipment for fiscal 2024 was $35.00K, a 74.45% decline from fiscal 2023.
- Trevi Therapeutics, Inc. payments to acquire property, plant, and equipment for fiscal 2023 was $137.00K, a 13.84% decline from fiscal 2022.
- Trevi Therapeutics, Inc. payments to acquire property, plant, and equipment for fiscal 2022 was $159.00K.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2026-06-30 | $124.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $226.00K 10-Q · filed 2026-08-06 | $226.00K derived: sum of 3 quarters · filed 2026-08-06 | $238.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $102.00K 10-Q · filed 2026-05-05 | $102.00K derived: sum of 2 quarters · filed 2026-05-05 | $114.00K derived: sum of 3 quarters · filed 2026-05-05 | |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $12.00K derived: sum of 2 quarters · filed 2026-03-17 | $12.00K 10-K · filed 2026-03-17 | |
| 2025-09-30 | $12.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $12.00K 10-Q · filed 2025-11-13 | ||
| 2025-06-30 | $0.00 10-Q · filed 2025-08-07 | |||
| 2024-12-31 | $7.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $7.00K derived: sum of 2 quarters · filed 2026-03-17 | $35.00K 10-K · filed 2026-03-17 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $28.00K 10-Q · filed 2025-11-13 | ||
| 2024-06-30 | $28.00K 10-Q · filed 2025-08-07 | |||
| 2023-12-31 | $22.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $40.00K derived: sum of 2 quarters · filed 2025-03-18 | $80.00K derived: sum of 3 quarters · filed 2025-03-18 | $137.00K 10-K · filed 2025-03-18 |
| 2023-09-30 | $18.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $58.00K derived: sum of 2 quarters · filed 2024-11-06 | $115.00K 10-Q · filed 2024-11-06 | $231.00K derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $40.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $97.00K 10-Q · filed 2024-08-08 | $213.00K derived: sum of 3 quarters · filed 2024-08-08 | |
| 2023-03-31 | $57.00K 10-Q · filed 2024-05-07 | $173.00K derived: sum of 2 quarters · filed 2024-05-07 | ||
| 2022-12-31 | $116.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-20 | $159.00K 10-K · filed 2024-03-20 | ||
| 2022-09-30 | $43.00K 10-Q · filed 2023-11-09 | |||
| 2020-12-31 | $5.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $20.00K derived: sum of 2 quarters · filed 2022-03-17 | $32.00K 10-K · filed 2022-03-17 | |
| 2020-09-30 | $15.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $27.00K 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | $12.00K 10-Q · filed 2021-08-12 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $0.00 derived: sum of 2 quarters · filed 2021-03-25 | $0.00 derived: sum of 3 quarters · filed 2021-03-25 | $9.00K 10-K · filed 2021-03-25 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $0.00 derived: sum of 2 quarters · filed 2020-11-12 | $9.00K 10-Q · filed 2020-11-12 | $101.00K derived: sum of 4 quarters · filed 2020-11-12 |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-13 | $9.00K 10-Q · filed 2020-08-13 | $101.00K derived: sum of 3 quarters · filed 2020-08-13 | $100.00K derived: sum of 4 quarters · filed 2020-08-13 |
| 2019-03-31 | $9.00K 10-Q · filed 2020-05-07 | $101.00K derived: sum of 2 quarters · filed 2020-05-07 | $100.00K derived: sum of 3 quarters · filed 2020-05-07 | $110.00K derived: sum of 4 quarters · filed 2020-05-07 |
| 2018-12-31 | $92.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $91.00K derived: sum of 2 quarters · filed 2020-03-16 | $101.00K derived: sum of 3 quarters · filed 2020-03-16 | $158.00K 10-K · filed 2020-03-16 |
| 2018-09-30 | -$1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $9.00K derived: sum of 2 quarters · filed 2019-11-14 | $66.00K 10-Q · filed 2019-11-14 | |
| 2018-06-30 | $10.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-12 | $67.00K 10-Q · filed 2019-08-12 | ||
| 2018-03-31 | $57.00K 10-Q · filed 2019-06-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |